Search Results - "Weems, Garry Alan"

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer by Camidge, D. Ross, Gadgeel, Shirish M., Weems, Garry Alan, Wilkins, H. Jeffrey, Johnson, Melissa Lynne

“…Abstract only…”
Get full text

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion by Hu, Xiao, Liu, Xikui, Li, Hongxiu, Zawidzka, Elizabeth, Weems, Garry Alan, Gao, Yilin, Fox, Brian, Wilkins, H. Jeffrey, Carter, Laura

“…Abstract only 424 Background: The master transcription factor retinoic acid receptor–related orphan receptor γt (RORγ) controls Type 17 effector T cell…”
Get full text

Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion by Weems, Garry Alan, Hu, Xiao, Liu, Xikui, Li, Hongxiu, Bogdan, Madhumita, Gao, Yilin, Fox, Brian, Wilkins, H. Jeffrey, Carter, Laura

“…Abstract only 67 Background: Type 17 effector T cell differentiation and function are regulated by the master transcription factor retinoic acid…”
Get full text

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors by Kelly, Karen, Johnson, Melissa Lynne, Mahalingam, Devalingam, Liu, Stephen V., Uronis, Hope Elizabeth, Wu, Christina, Carter, Laura, Hu, Xiao, Weems, Garry Alan, Wilkins, H. Jeffrey, Duska, Linda R.

“…Abstract only…”
Get full text

Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder by Loriot, Yohann, Fizazi, Karim, Carles, Joan, Weems, Garry Alan, Chance, Lacey, Agarwal, Neeraj

“…Abstract only 4574 Background: Antifolate agents have demonstrated activity in transitional cell carcinoma (TCC), a disease with very poor outcomes in advanced…”
Get full text